Atea Pharmaceuticals director proposes $60.8K sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
144
Rhea-AI Filing Summary
Atea Pharmaceuticals, Inc. (AVIR) director Bruce Polsky reported a proposed sale of 14,254 common shares, with an aggregate market value of $60,840.35 and an approximate sale date of November 16, 2026.
Key Figures
Shares proposed for sale: 14,254 shares
Aggregate market value: $60,840.35
Shares outstanding: 80,304,145 shares
3 metrics
Shares proposed for sale
14,254 shares
Approximate sale date November 16, 2026
Aggregate market value
$60,840.35
For the 14,254 common shares proposed for sale
Shares outstanding
80,304,145 shares
Reported shares outstanding for Atea Pharmaceuticals, Inc.
Key Terms
Stock Option Exercise
1 terms
Stock Option Exercise financial
"Nature of Acquisition Transaction: Stock Option Exercise"
A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.